RECRUITING

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Description

The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.

Conditions

Prurigo Nodularis
Talk to us

Related Conditions:

Prurigo Nodularis

Study Overview

On this page

Study Details

Study overview

The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults

Condition
Prurigo Nodularis
Intervention / Treatment

-

Contacts and Locations

Birmingham

Galderma Investigational Site # 8893, Birmingham, Alabama, United States, 35244

Phoenix

Galderma Investigational Site # 7077, Phoenix, Arizona, United States, 85006-2754

Phoenix

Galderma Investigational Site # 7060, Phoenix, Arizona, United States, 85008-3884

Tucson

Galderma Investigational Site # 7067, Tucson, Arizona, United States, 85718

Corona

Galderma Investigational Site # 7074, Corona, California, United States, 92882

Fountain Valley

Galderma Investigational Site # 6836, Fountain Valley, California, United States, 92708-3701

Fremont

Galderma Investigational Site # 8224, Fremont, California, United States, 94538-1603

Santa Monica

Galderma Investigational Site # 7064, Santa Monica, California, United States, 90404-2216

Castle Rock

Galderma Investigational Site # 7061, Castle Rock, Colorado, United States, 80109-8034

Fairfield

Galderma Investigational Site # 7059, Fairfield, Connecticut, United States, 06824

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.
  • * Participants greater than or equal to (\>=) 18 years of age.
  • * Participants who signed the written informed consent form (ICF).
  • * Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label;
  • * Participants who received treatment with a drug under clinical development/ investigation within 3 months prior to baseline.
  • * Participants who received nemolizumab previously.
  • * Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Galderma R&D,

Study Record Dates

2027-11-30